Cephalon's Myotrophin
Executive Summary
Receives orphan drug designation for its recombinant IGF-1 (insulin-like growth factor), the West Chester, Pa.-based company announces Oct. 25. The drug is indicated for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). The company estimates that there currently are over 30,000 people in the U.S. with ALS....